US 12,428,404 B2
Inhibitors of LRRK2 kinase
David James Bearss, Lehi, UT (US); John Sai Keong Kauwe, III, Lehi, UT (US); and Alexis Henri Abel Mollard, Lehi, UT (US)
Assigned to Halia Therapeutics, Inc., Lehi, UT (US)
Filed by Halia Therapeutics, Inc., Lehi, UT (US)
Filed on Nov. 20, 2023, as Appl. No. 18/514,959.
Application 18/065,259 is a division of application No. 17/702,600, filed on Mar. 23, 2022, granted, now 11,578,061, issued on Feb. 14, 2023.
Application 18/514,959 is a continuation of application No. 18/065,259, filed on Dec. 13, 2022, granted, now 11,866,423.
Claims priority of provisional application 63/164,804, filed on Mar. 23, 2021.
Prior Publication US 2024/0190848 A1, Jun. 13, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 239/47 (2006.01); A61K 31/505 (2006.01); A61K 31/506 (2006.01); C07D 401/14 (2006.01); C07D 403/12 (2006.01); C07D 403/14 (2006.01); C07D 405/14 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 491/107 (2006.01); C07D 498/08 (2006.01)
CPC C07D 403/14 (2013.01) [C07D 239/47 (2013.01); C07D 401/14 (2013.01); C07D 403/12 (2013.01); C07D 405/14 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 491/107 (2013.01); C07D 498/08 (2013.01)] 22 Claims
 
1. A compound having the following Structure (I):

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, or stereoisomer thereof, wherein:
A is phenylene or 5 or 6-membered heteroarylene;
B is C3-C8 monocyclic cycloalkyl optionally substituted with one or more substituents selected from amino, halo, hydroxyl, oxo, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 hydroxylalkyl, C1-C6 aminoalkyl, C1-C6 alkylaminylalkyl, C1-C6 alkoxy; C1-C6 haloalkoxy, C1-C6 alkylcarbonyl, C1-C6 haloalkylcarbonyl, C1-C6 alkylaminyl, C1-C6 haloalkylaminyl, C1-C6 alkylcarbonylaminyl, C1-C6 haloalkylcarbonylaminyl, C3-C8 cycloalkyl, C3-C8 cycloalkylcarbonyl, C3-C8 halocycloalkylaminyl, and C3-C8 cycloalkylcarbonylaminyl;
L is a direct bond;
R1a and R1b are each independently H, halo, cyano, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C3-C8 cycloalkyl; and
R2 is 3-8-membered heterocyclyl optionally substituted with one or more substituents selected from halo, cyano, C1-C6 alkyl, hydroxyl, alkoxy, and C1-C6 haloalkyl.